ArticleAmerican journal of translational research2025
Development of a novel circulating miRNA panel for early detection of esophageal cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesEsophageal cancer (EC) is a highly aggressive malignancy with a low survival rate. Current detection methods like endoscopy are invasive and expensive, resulting in low compliance rates. This study aimed to develop and validate a novel circulating microRNA (miRNA)-based panel for early EC detection and compare its effectiveness in serum versus plasma samples.
methodsThe study developed a multiplexed miRNA assay to detect eight EC-related miRNAs in both plasma (n=45) and serum (n=148) samples. Expression levels of these miRNAs were compared between EC patients and control subjects. The serum-based panel was further validated in an independent cohort and compared with carcinoembryonic antigen (CEA), a conventional tumor marker.
resultsThe multiplexed miRNA panel demonstrated excellent PCR amplification efficiency with no cross-interference between miRNAs. Six of the eight miRNAs showed significantly higher expression in EC patients compared to controls in serum samples (area under the curve (AUC) >0.900), while plasma samples showed poor discrimination (AUC<0.700). The optimized 6-miRNA panel in serum achieved perfect discrimination (AUC=1.0) between EC and controls in both training and validation cohorts. This panel also effectively distinguished EC from gastric and colorectal cancers and significantly outperformed CEA (AUC=0.619) in diagnostic accuracy.
conclusionSerum is more suitable than plasma for EC detection using miRNA biomarkers. The optimized 6-miRNA panel demonstrated exceptional accuracy for EC detection, offering a promising non-invasive approach for early diagnosis. This method requires smaller sample volumes than traditional techniques, potentially improving clinical applicability and patient compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.